title: Chemokines in aqueous humour before and after intravitreal triamcinolone acetonide in eyes with macular oedema associated with branch retinal vein occlusion.
abstract: OBJECTIVE
  To determine the aqueous humour levels of chemokines before and after an intravitreal injection of triamcinolone acetonide (IVTA) in eyes with macular oedema associated with a branch retinal vein occlusion (ME-BRVO).
  
  
  METHODS
  Single-centre, prospective, consecutive interventional case series.
  
  
  METHODS
  Seventeen eyes of 17 consecutive patients with ME-BRVO who underwent IVTA were studied. Seven eyes without retinal vascular disease served as control.
  
  
  METHODS
  All patients with ME-BRVO underwent IVTA.
  
  
  METHODS
  The optical coherence tomographically determined foveal thickness (FT) and the aqueous humour levels of inflammatory chemokines of the C-C subfamily, including eotaxin, monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), β (MIP-1β), and RANTES was determined before the IVTA (baseline) and at 1 week after the IVTA.
  
  
  RESULTS
  At the baseline, only MCP-1 and MIP-1β were detected in the aqueous, and MIP-1β was significantly higher in eyes with a ME-BRVO than in controls (p = 0.004). The level of both of these chemokines was not correlated with the FT (p = 0.654 and p = 0.608, respectively). One week after IVTA, the FT was significantly decreased (p < 0.001), and the levels of MCP-1 and MIP-1β were also significantly reduced (p < 0.001 and p = 0.044, respectively). The decrease in the FT was correlated with the decrease in only MIP-1β (r = 0.58, p = 0.020).
  
  
  CONCLUSIONS
  Alterations of the aqueous level of MIP-1β reflect the improvement of the macular oedema after IVTA in eyes with ME-BRVO. This indicates that the steroid-dependent ME-BRVO was closely related with the level of MIP-1β.
authors.affiliation: Department of Ophthalmology and Visual Science, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan. kunikata@oph.med.tohoku.ac.jp
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kunikata
authors.forename: Masahiko
authors.initials: M
authors.lastname: Shimura
authors.forename: Toru
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Koh-Hei
authors.initials: KH
authors.lastname: Sonoda
authors.forename: Takeru
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Kohji
authors.initials: K
authors.lastname: Nishida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001082:Aqueous Humor / Q000378:metabolism*; D018932:Chemokine CCL2 / Q000378:metabolism; D054407:Chemokine CCL4 / Q000378:metabolism; D018925:Chemokines / Q000378:metabolism*; D005260:Female; D005584:Fovea Centralis / Q000473:pathology; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000188:drug therapy* / Q000378:metabolism; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
chemical_list: C111835:CCL2 protein, human; C066507:CCL4 protein, human; D018932:Chemokine CCL2; D054407:Chemokine CCL4; D018925:Chemokines; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide